June 2008
BioWorld Today;6/3/2008, Vol. 19 Issue 107, p12
This section offers news briefs on clinical trials of various drugs as of June 2008. AMAG Pharmaceuticals Inc. reported positive results from two Phase III studies of ferumoxytol as iron replacement therapeutic agent in patients with chronic kidney disease with functioning kidney transplants. Hemispherx Biopharma Inc. announced that it completed enrollment in a Phase II trial to evaluate Ampligen as an enhancer for seasonal influenza vaccine. Human Genome Sciences Inc. started dosing in a Phase I study of its lead IAP inhibitor, HGS1029.


Related Articles

  • HEMISPHERX COMPLETES ENROLLMENT IN PHASE II AMPLIGEN STUDY.  // Worldwide Biotech;Jul2008, Vol. 20 Issue 7, p8 

    The article reports the start of Phase II clinical trial of Ampligen (r) as seasonal flue vaccine enhancer has been completed by Hemispherx Biopharma Inc. in Australia. The company will evaluate the safety and efficacy of Ampligen (r) as an enhanser for seasonal flu vaccine. The secondary goal...

  • HEMISPHERX INITIATES AMPLIGEN PHASE IIB FOR INFLUENZA.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p2 

    The article reports that the Ampligen Phase IIB trial for influenza was initiated by the Hemispherx Biopharma, Inc. in Australia. The Japanese National Institute of Infectious Diseases (JIID) reported robust immune responses in animals when Ampligen (r) was added to either avian or seasonal...

  • Chronic tonic.  // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p134 

    Announces a Phase III clinical study of Hemispherx Biopharma's clinical study of its drug Ampligen. Details on the placebo-controlled study; Results of earlier trial.

  • Human Genome Sciences/GSK: positive data buck the systemic lupus erythematosus trend.  // PharmaWatch: Biotechnology;Sep2009, Vol. 8 Issue 9, p9 

    The article reports on the progress of the Phase III clinical trial for Benlysta or belimumab drug for the treatment of systemic lupus erythematosus (SLE). It mentions that the lupus drug, which is developed by Human Genome Sciences Inc. (HGS) and GlaxoSmithKline (GSK), will be the first SLE...

  • Street Thrown for a 'Lupus' as HGS Posts Phase III Win. Osborne, Randy // BioWorld Today;7/21/2009, Vol. 20 Issue 138, p1 

    The article reports on the positive results released by Human Genome Sciences Inc. (HGS) regarding a Phase III lupus trial of its Benlysta. Gary Gilkeson of Medical University of South Carolina claims that all the patients who enrolled for the trial did well on Benlysta. The company is planning...

  • EASL Roundup.  // BioWorld Today;4/28/2009, Vol. 20 Issue 80, p6 

    The article offers a look at the final results of the two Phase III clinical trials presented by Human Genome Sciences Inc. The two clinical drug trials compare ribavirin plus Albuferon (albinterferon alfa-2b) dosed every two weeks to ribavirin plus Pegasys (pegylated interferon alfa-2a) dosed...

  • HGS Posts Phase III Lupus Win.  // Bioworld Week;7/27/2009, Vol. 17 Issue 30, p2 

    The article reports on the promise of Human Genome Sciences Inc. (HGS) to investors over the positive top-line results of its Benlysta Phase III study. It notes that the endpoint of the study depicts the reduction of four points from baseline in the SELENA SLEDAI score, associated with lupus,...

  • Iron wrinkle: CRL delays Amag's taking on 'slow-start' Injectafer. Osborne, Randy // BioWorld Today;1/23/2014, Vol. 25 Issue 15, p1 

    The article focuses on the delaying of supplemental new drug application (sNDA) for intravenous Feraheme by Amag Pharmaceuticals Inc., Massachusetts. Topics discussed include Amag is hoping to expand the approved indication for Feraheme beyond chronic kidney disease (CKD), Food and drug...

  • U.S. Patent Disclosures.  // BioWorld Today;8/15/2011, Vol. 22 Issue 157, p4 

    The article announces the granting of U.S. patents for biotechnology firms in 2011. Alethia Biotherapeutics Inc. received a patent for "Polynucleotide and Polypeptide Sequences Involved in the Process of Bone Remodeling." Convergen LifeSciences was given a patent for the CNVN202 targeted...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics